Prostate cancer that spreads to the bone triggers the destruction of bone tissue that thwarts the effectiveness of immune checkpoint inhibitors. Research points to anti-CTLA-4 and anti-TGF-B combination to protect T cells.
12-Nov-2019 1:35 PM EST Add to Favorites
Researchers from The University of Texas MD Anderson Cancer Center reported that secondary tumor-reduction, or cytoreduction, surgery followed by chemotherapy did not result in longer survival than chemotherapy alone in patients with...
12-Nov-2019 10:00 AM EST Add to Favorites
MD Anderson, Artios Pharma and ShangPharma announce in-licensing agreement for DNA damage response inhibitor
MD Anderson, Artios and ShangPharma have announced the in-licensing by Artios of a small-molecule ATR inhibitor program, developed jointly by MD Anderson and ShangPharma.
6-Nov-2019 3:40 PM EST Add to Favorites
MD Anderson and Takeda Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
MD Anderson and Takeda today announced an exclusive license agreement and research agreement to develop CAR NK-cell therapies for the the treatment of B-cell malignancies.
5-Nov-2019 7:00 AM EST Add to Favorites
Ziopharm and MD Anderson have announced a new research and development agreement to develop novel T-cell therapies using engineered T-cell receptors for solid tumors.
28-Oct-2019 8:05 AM EDT Add to Favorites
Seven business and community leaders from across the nation join MD Anderson Cancer Center Board of Visitors.
24-Oct-2019 12:00 PM EDT Add to Favorites
The University of Texas MD Anderson Cancer Center and Varian today announced a new strategic collaboration to develop an integrated software platform to streamline review of radiation oncology treatment plans.
16-Oct-2019 3:15 PM EDT Add to Favorites
The North Texas A Conversation With a Living Legend® will honor Los Angeles Dodgers starting pitcher Clayton Kershaw in an interview with CBS News' Bob Schieffer. The luncheon benefits the Moon Shots Program®.
15-Oct-2019 10:00 AM EDT Add to Favorites
see all news
Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer
In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT
It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT
Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT
A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT
MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System
The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT
Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST
30-Oct-2013 8:10 PM EDT
30-Oct-2013 8:00 PM EDTsee all experts